Potential Benefits of Analyzing Circulating Microvesicles for Cancer Detection and Monitoring Showcased at the 2011 Annual Meeting of the American Association for Cancer Research

Five Presented Posters Demonstrate Promise of New Technology Being Developed for Cancer Testing
IRVING, TX, April 7, 2011 — Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, this weekend presented significant findings regarding the potential role of circulating microvesicles (cMV) as a non-invasive blood-based testing technology at the American Association for Cancer Research (AACR) annual meeting. The data presented supports the potential of cMV in the development of various blood-based diagnostic, prognostic and theranostic tests, as well as for therapeutic response measurement. Being developed by Caris Life Sciences, under the trade name Carisome™, this versatile blood-based technology is being studied for potential utility as an aid in the diagnosis of common cancers such as colon, breast, lung and prostate cancer, as well as other complex diseases.
A summary of each AACR poster presented follows:

  • “Subpopulations of circulating microvesicles have different microRNA profiles,” highlighted the diagnostic, prognostic, and theranostic implications associated with isolating tissue-specific cMV populations from patient plasma based on surface protein composition.
  • “Plasma-derived circulating microvesicles can both detect and help monitor breast cancer-related pathologies,” showed that in addition to aiding diagnosis, monitoring specific subpopulations of cMV may offer important biologic information processes perturbed by breast cancer.
  • “Enriching for rare subpopulations of circulating microvesicles by the depletion of endothelial- and leukocyte-derived microvesicles,” suggested a potential method for a more complete characterization of biomarker profiles associated with cMV derived from disease-associated cells.
  • “Detection of lung cancer from plasma using the biosignature of circulating microvesicles,” provided initial evidence that the identification of biosignatures in distinct subpopulations of cMV may offer a powerful blood-based approach for the detection and monitoring of specific disease states.
  • “Comparison of miR expression patterns in plasma, serum, and cell line cMV,” demonstrated that circulating microvesicles isolated from the peripheral blood offer a unique and potentially clinically relevant source of miR for blood-based analysis.

“The importance of personalized medicine tools continues to grow, and we believe the next frontier is represented by Caris’ circulating microvesicle research efforts, commented Les Paul, MD, Senior Vice President for Research and Development and Chief Technology Officer. “This technology platform has the potential to identify disease-associated circulating microvesicles in the blood, showing promise for clinical utility in early diagnostic testing, disease monitoring, and therapeutic response.”
Caris Life Sciences’ Carisome Technology represents the potential to transform healthcare with blood-based diagnostics, prognostics and therapeutic guidance that aid clinicians and their patients with treatment decisions. Caris’ work in this area includes major advances in the understanding of cMV and their potential application to patient care, through more accurate diagnosis and therapeutic planning.
About Caris Life Sciences
Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing a series of blood tests utilizing the patented Carisome™ platform — a proprietary, blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. The company is headquartered in the Dallas metroplex, and operates laboratories at the headquarters, as well as in the Phoenix and Boston metro areas.
Caris Life Sciences
Media Inquiries:
Holly Clark
Contact Holly